Zafgen (Zafgen) Net Income From Continuing Operations : $-35.89 Mil (TTM As of Mar. 2020)

View and export this data going back to 2014. Start your Free Trial

What is Zafgen Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Zafgen's net income from continuing operations for the three months ended in Mar. 2020 was $-3.60 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2020 was $-35.89 Mil.

Zafgen Net Income From Continuing Operations Historical Data

The historical data trend for Zafgen's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zafgen Net Income From Continuing Operations Chart

Zafgen Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Net Income From Continuing Operations

Get a 7-Day Free Trial

-74.29

-57.88

-52.03

-61.37

-45.41

Zafgen Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20
Net Income From Continuing Operations	Get a 7-Day Free Trial															-13.11	-12.13	-12.91	-7.25	-3.60

Zafgen Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-35.89 Mil.

Zafgen (Zafgen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zafgen Inc (NAS:ZFGN) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

N/A

Address

3 Center Plaza, Suite 610, Boston, MA, USA, 02108

Website

http://www.zafgen.com

Zafgen Inc is a US-based biopharmaceutical company. It focuses on developing novel therapeutics that treat the underlying biological mechanisms through the methionine aminopeptidase 2, or MetAP2, pathway. The lead product candidate of the company is ZGN-1061 which is a novel fumagillin-class MetAP2 inhibitor administered by subcutaneous injection. The company operates in the business of developing novel therapeutics. The company primarily carries its business operations in the United States.